zabmedvestnikЗабайкальский медицинский вестникTransbaikalian Medical Bulletin1998-6173Читинская государственная медицинская академия10.52485/19986173_2022_4_122zabmedvestnik-108Research ArticleНАУЧНЫЕ ОБЗОРЫSCIENTIFIC REVIEWSМедикаментозно-индуцированная (стероидная) офтальмогипертензия и глаукомаDrug-induced (steroid) glaucoma and ophthalmic hypertensionТаскинаЕ. С.TaskinaE. S.

672000, г. Чита, ул. Горького, 39а

39a Gorky Street, Chita, 6720000

ХаринцеваС. В.KharintsevaS. V.

672000, г. Чита, ул. Горького, 39а

39a Gorky Street, Chita, 6720000

ПросекинаЕ. В.ProsekinaE. V.

672000, г. Чита, ул. Горького, 39а

39a Gorky Street, Chita, 6720000

Федеральное государственное бюджетное образовательное учреждение высшего образования «Читинская государственная медицинская академия» Министерства здравоохранения Российской ФедерацииРоссияChita State Medical AcademyRussian Federation20220208202404122131Copyright © Таскина Е.С., Харинцева С.В., Просекина Е.В., 20242024Таскина Е.С., Харинцева С.В., Просекина Е.В.Taskina E.S., Kharintseva S.V., Prosekina E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.zabmedvestnik.ru/jour/article/view/108

Актуальность проблемы развития медикаментозно-индуцированной (стероидной) офтальмогипертензии и глаукомы обусловлена широким назначением глюкортикоидов в лечении офтальмологических и системных заболеваний. Внутриглазное давление может повышаться при различных путях введения глюкортикоидов, в разные сроки лечения, а также способно самостоятельно купироваться после отмены данных лекарственных средств. При длительном бесконтрольном назначении глюкортикоидов возможно стойкое морфологическое поражение зрительного нерва с периметрическими потерями. В обзоре литературы представлены факторы риска, механизмы нарушения гидродинамики глаза, особенности клинического течения и принципы терапии вторичной стероидной офтальмогипертензии и глаукомы.

Drug-induced (steroid) ophthalmohypertension and glaucoma is an actual problem due to the widespread use of glucocorticoids in treatment of various ocular and systemic diseases. Intraocular pressure may increase with different routes of glucocorticoid administration, at different times of treatment and can also stop on its own after discontinuation of these drugs. Prolonged uncontrolled glucocorticoid administration may cause persistent morphological optic nerve damage with perimetric loss. The literature review presents risk factors, mechanisms of eye hydrodynamic disturbances, clinical course features and principles of secondary steroid ophthalmohypertension and glaucoma treatment.

Глюкортикоидыофтальмогипертензиястероидная глаукомафакторы рискапатогенездиагностикалечениеGlucorticoidsophthalmohypertensionsteroid-induced glaucomarisk factorspathogenesisdiagnosistreatmentReferencesGloria R., Oddone F., Agnifili L., Katsanos A., Michelessi M., Mastropasqua L., Quaranta L., Riva I., Tanga L., Manni G. Steroid-induced glaucoma: Epidemiology, pathophysiology, and clinical management. Surv Ophthalmol. 2020. 65(4). 458-472. DOI: 10.1016/j.survophthal.2020.01.002.Gloria R., Oddone F., Agnifili L., Katsanos A., Michelessi M., Mastropasqua L., Quaranta L., Riva I., Tanga L., Manni G. Steroid-induced glaucoma: Epidemiology, pathophysiology, and clinical management. Surv Ophthalmol. 2020. 65(4). 458-472. DOI: 10.1016/j.survophthal.2020.01.002.Steven T., Souffriau J., Libert C. A General Introduction to Glucocorticoid Biology. Front Immunol. 2019. 10. 15-45. DOI:10.3389/fimmu.2019.01545.Steven T., Souffriau J., Libert C. A General Introduction to Glucocorticoid Biology. Front Immunol. 2019. 10. 15-45. DOI:10.3389/fimmu.2019.01545.Борисова Е.О. Нежелательные эффекты системной глюкокортикостериодной терапии. Клиническая геронтология. 2009. 8-9. 19-26.Borisova E.O. Undesirable effects of systemic glucocorticosteroid therapy. Clinical gerontology. 2009. 8-9. 19-26. in Russian.Витовская О.П. Медикаментозно индуцированная глаукома. Офтальмологические ведомости. 2014. 3. 58-62.Vitovskaya O.P. Medically induced glaucoma. Ophthalmological records. 2014. 3. 58-62. in Russian.Musleh M.G., Bokre D., Dahlmann-Noor A.H. Risk of intraocular pressure elevation after topical steroids in children and adults: A systematic review. Eur J Ophthalmol. 2020. 30(5). 856-866. DOI: 10.1177/1120672119885050.Musleh M.G., Bokre D., Dahlmann-Noor A.H. Risk of intraocular pressure elevation after topical steroids in children and adults: A systematic review. Eur J Ophthalmol. 2020. 30(5). 856-866. DOI: 10.1177/1120672119885050.McLean J.M. Use of ACTH and cortisone Trans. Am. Ophthalmol Soc. 1950. 48. 293-296.McLean J.M. Use of ACTH and cortisone Trans. Am. Ophthalmol Soc. 1950. 48. 293-296.Francois J. Cortisone et tension oculaire. Ann D’Oculist. 1954. 187. 805.Francois J. Cortisone et tension oculaire. Ann D’Oculist. 1954. 187. 805.Armaly M.F. Statistical attributes of the steroid hypertensive response in the clinically normal eye. 1. The demonstration of three level of response. Invest Opbtbalmol. 1963. 4. 187-197.Armaly M.F. Statistical attributes of the steroid hypertensive response in the clinically normal eye. 1. The demonstration of three level of response. Invest Opbtbalmol. 1963. 4. 187-197.Nuyen B., Weinreb R.N., Robbins S.L. Steroid-induced glaucoma in the pediatric population. J AAPOS. 2017. 21(1). 1-6. DOI: 10.1016/j.jaapos.2016.09.026.Nuyen B., Weinreb R.N., Robbins S.L. Steroid-induced glaucoma in the pediatric population. J AAPOS. 2017. 21(1). 1-6. DOI: 10.1016/j.jaapos.2016.09.026.Choi W., Bae H.W., Choi E.Y., Kim M., Kim E.W., Kim C.Y., Kim M., Seong G.J. Age as a risk factor for steroid-induced ocular hypertension in the non-paediatric population. Br J Ophthalmol. 2020. 104(10). 1423-1429. DOI: 10.1136/bjophthalmol-2019-314559.Choi W., Bae H.W., Choi E.Y., Kim M., Kim E.W., Kim C.Y., Kim M., Seong G.J. Age as a risk factor for steroid-induced ocular hypertension in the non-paediatric population. Br J Ophthalmol. 2020. 104(10). 1423-1429. DOI: 10.1136/bjophthalmol-2019-314559.Gupta S., Shah P., Grewal S., Chaurasia A.K., Gupta V. Steroid-induced glaucoma and childhood blindness. Br J Ophthalmol. 2015. 99(11). 1454-1456. DOI: 10.1136/bjophthalmol-2014-306557.Gupta S., Shah P., Grewal S., Chaurasia A.K., Gupta V. Steroid-induced glaucoma and childhood blindness. Br J Ophthalmol. 2015. 99(11). 1454-1456. DOI: 10.1136/bjophthalmol-2014-306557.Lam D.S.C., Fan D.S.P., Ng J.S.K., Yu C.B.O., Wong C.Y., Cheung A.Y.K. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin. Exp. Ophthalmol. 2005. 33. 252-258. DOI: 10.1111/j.1442-9071.2005.01022.x.Lam D.S.C., Fan D.S.P., Ng J.S.K., Yu C.B.O., Wong C.Y., Cheung A.Y.K. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin. Exp. Ophthalmol. 2005. 33. 252-258. DOI: 10.1111/j.1442-9071.2005.01022.x.Armaly M.F. Effect of corticosteroids on intraocular pressure and fluid dynamics: II. The effect of dexamethasone on the glaucomatous eye. Arch. Ophthalmol. 1963. 70. 492-499.Armaly M.F. Effect of corticosteroids on intraocular pressure and fluid dynamics: II. The effect of dexamethasone on the glaucomatous eye. Arch. Ophthalmol. 1963. 70. 492-499.Zhang X., Ognibene C.M., Clark A.F., Yorio T. Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta. Exp Eye Res. 2007. 84(2). 275-284. DOI: 10.1016/j.exer.2006.09.022.Zhang X., Ognibene C.M., Clark A.F., Yorio T. Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta. Exp Eye Res. 2007. 84(2). 275-284. DOI: 10.1016/j.exer.2006.09.022.Buttgereit F., Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids. 2002. 67. 529- 534. DOI: 10.1016/S0039-128X(01)00171-4.Buttgereit F., Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids. 2002. 67. 529- 534. DOI: 10.1016/S0039-128X(01)00171-4.Stahn C., Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008. 4. 525-533. DOI: 10.1038/ncprheum0898.Stahn C., Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008. 4. 525-533. DOI: 10.1038/ncprheum0898.Umberto M.G., Chrousos G.P. General Adaptation in Critical Illness: Glucocorticoid Receptor- alpha Master Regulator of Homeostatic Corrections. Front Endocrinol (Lausanne). 2020. 11. 161. DOI:10.3389/fendo.2020.0016.Umberto M.G., Chrousos G.P. General Adaptation in Critical Illness: Glucocorticoid Receptor- alpha Master Regulator of Homeostatic Corrections. Front Endocrinol (Lausanne). 2020. 11. 161. DOI:10.3389/fendo.2020.0016.Ioanna P., Dejager L., Ballegeer M., Lievens S., Tavernier J., Bosscher K.De, Libert C. The Interactome of the Glucocorticoid Receptor and Its Influence on the Actions of Glucocorticoids in Combatting Inflammatory and Infectious Diseases. Microbiol Mol Biol Rev. 2016. 80(2). 495- 522. DOI:10.1128/MMBR.Ioanna P., Dejager L., Ballegeer M., Lievens S., Tavernier J., Bosscher K.De, Libert C. The Interactome of the Glucocorticoid Receptor and Its Influence on the Actions of Glucocorticoids in Combatting Inflammatory and Infectious Diseases. Microbiol Mol Biol Rev. 2016. 80(2). 495- 522. DOI:10.1128/MMBR.Escoter-Torres L., Caratti G., Mechtidou A., Tuckermann J., Uhlenhaut N.H., Vettorazzi S. Fighting the Fire: Mechanisms of Inflammatory Gene Regulation by the Glucocorticoid Receptor. Front Immunol. 2019. 10. 1859. DOI:10.3389/fimmu.2019.01859.Escoter-Torres L., Caratti G., Mechtidou A., Tuckermann J., Uhlenhaut N.H., Vettorazzi S. Fighting the Fire: Mechanisms of Inflammatory Gene Regulation by the Glucocorticoid Receptor. Front Immunol. 2019. 10. 1859. DOI:10.3389/fimmu.2019.01859.Vranka J.A., Kelley M.J., Acott T.S., Keller K.E. Extracellular matrix in the trabecular meshwork: intraocular pressure regulation and dysregulation in glaucoma. Experimental eye research. 2015. 133. 112-125. DOI: 10.1016/j.exer.2014.07.014.Vranka J.A., Kelley M.J., Acott T.S., Keller K.E. Extracellular matrix in the trabecular meshwork: intraocular pressure regulation and dysregulation in glaucoma. Experimental eye research. 2015. 133. 112-125. DOI: 10.1016/j.exer.2014.07.014.Clark A.F., Wordinger R.J. The role of steroids in outflow resistance. Exp Eye Res. 2009. 88. 752-759. DOI: 10.1016/j.exer.2008.10.004.Clark A.F., Wordinger R.J. The role of steroids in outflow resistance. Exp Eye Res. 2009. 88. 752-759. DOI: 10.1016/j.exer.2008.10.004.Overby D.R., Clark A.F. Animal models of glucocorticoid-induced glaucoma. Exp Eye Res. 2015. 141. 15-22. DOI: 10.1016/j.exer.2015.06.002.Overby D.R., Clark A.F. Animal models of glucocorticoid-induced glaucoma. Exp Eye Res. 2015. 141. 15-22. DOI: 10.1016/j.exer.2015.06.002.Yun A.J., Murphy C.G., Polansky J.R., Newsome D.A., Alvarado J.A. Proteins secreted by human trabecular cells: glucocorticoid and other effects. Invest Ophthalmol Vis Sci. 1989. 30. 2012-2022.Yun A.J., Murphy C.G., Polansky J.R., Newsome D.A., Alvarado J.A. Proteins secreted by human trabecular cells: glucocorticoid and other effects. Invest Ophthalmol Vis Sci. 1989. 30. 2012-2022.Zode G.S., Kuehn M.H., Nishimura D.Y., Searby C.C., Mohan K., Grozdanic S.D., Bugge K., Anderson M.G., Clark A.F., Stone E.M., Sheffield V.C. Reduction of ER stress via a chemical chaperone prevents disease phenotypes in a mouse model of primary open angle glaucoma. J Clin Invest. 2015. 125. 3303. DOI: 10.1172/JCI58183.Zode G.S., Kuehn M.H., Nishimura D.Y., Searby C.C., Mohan K., Grozdanic S.D., Bugge K., Anderson M.G., Clark A.F., Stone E.M., Sheffield V.C. Reduction of ER stress via a chemical chaperone prevents disease phenotypes in a mouse model of primary open angle glaucoma. J Clin Invest. 2015. 125. 3303. DOI: 10.1172/JCI58183.Patel G.C., Phan T.N., Maddineni P., Kasetti R.B., Millar J.C., Clark A.F., Zode G.S. Dexamethasone induced ocular hypertension in mice: effects of myocilin and route of administration. Am J Pathol. 2017. 187(4). 713-723. DOI: 10.1016/j.ajpath.2016.12.003.Patel G.C., Phan T.N., Maddineni P., Kasetti R.B., Millar J.C., Clark A.F., Zode G.S. Dexamethasone induced ocular hypertension in mice: effects of myocilin and route of administration. Am J Pathol. 2017. 187(4). 713-723. DOI: 10.1016/j.ajpath.2016.12.003.Sheppard J.D., Comstock T.L., Cavet M.E. Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. Adv Ther. 2016. 33. 532-552. DOI: 10.1007/s12325-016-0315-8.Sheppard J.D., Comstock T.L., Cavet M.E. Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. Adv Ther. 2016. 33. 532-552. DOI: 10.1007/s12325-016-0315-8.Kiddee W., Trope G., Sheng L., Beltran-Agullo L., Smith M., Strungaru M., Baath J., Buys Y. Intraocular Pressure Monitoring Post Intravitreal Steroids: A Systematic Review. Survey of Ophthalmology. 2013. 58(4). 291-310. DOI: 10.1016/j.survophthal.2012.08.003.Kiddee W., Trope G., Sheng L., Beltran-Agullo L., Smith M., Strungaru M., Baath J., Buys Y. Intraocular Pressure Monitoring Post Intravitreal Steroids: A Systematic Review. Survey of Ophthalmology. 2013. 58(4). 291-310. DOI: 10.1016/j.survophthal.2012.08.003.Yuksel-Elgin C., Elgin C. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection: a Meta-analysis. Int J Ophthalmol. 2016. 9(1). 139-144. DOI: 10.18240/ijo.2016.01.23.Yuksel-Elgin C., Elgin C. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection: a Meta-analysis. Int J Ophthalmol. 2016. 9(1). 139-144. DOI: 10.18240/ijo.2016.01.23.Ghoneim E.M., Abd E.l., Ghany A.A. Behavior of intraocular pressure after intravitreal injection of triamcinolone acetonide among Egyptians. Ophthalmol Ter. 2013. 2(2). 121-130. DOI: 10.1007/s40123-013-0017-0.Ghoneim E.M., Abd E.l., Ghany A.A. Behavior of intraocular pressure after intravitreal injection of triamcinolone acetonide among Egyptians. Ophthalmol Ter. 2013. 2(2). 121-130. DOI: 10.1007/s40123-013-0017-0.Goni F. J., Stalmans I., Denis P., Nordmann J.-P., Taylor S., Diestelhorst M., Figueiredo A.R., Garway-Heath D.F. Elevated Intraocular Pressure after Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management. Ophthalmology and Therapy. 2016. 5(1). 47-61. DOI: 10.1007/s40123-016-0052-8.Goni F. J., Stalmans I., Denis P., Nordmann J.-P., Taylor S., Diestelhorst M., Figueiredo A.R., Garway-Heath D.F. Elevated Intraocular Pressure after Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management. Ophthalmology and Therapy. 2016. 5(1). 47-61. DOI: 10.1007/s40123-016-0052-8.Groth S.L., Albeiruti E., Nunez M., Fajardo R., Sharpsten L., Loewen N., Schuman J.S., Goldberg J.L. SALT Trial: Steroids after Laser Trabeculoplasty: Impact of Short-Term Anti-inflammatory Treatment on Selective Laser Trabeculoplasty Efficacy. Ophthalmology. 2019. 126(11). 1511- 1516. DOI: 10.1016/j.ophtha.2019.05.032.Groth S.L., Albeiruti E., Nunez M., Fajardo R., Sharpsten L., Loewen N., Schuman J.S., Goldberg J.L. SALT Trial: Steroids after Laser Trabeculoplasty: Impact of Short-Term Anti-inflammatory Treatment on Selective Laser Trabeculoplasty Efficacy. Ophthalmology. 2019. 126(11). 1511- 1516. DOI: 10.1016/j.ophtha.2019.05.032.Candia O.A., Gerometta R.M., Danias J. Tissue plasminogen activator reduces the elevated intraocular pressure induced by prednisolone in sheep. Exp Eye Res. 2014. 128. 114-116. DOI: 10.1016/j.exer.2014.10.004.Candia O.A., Gerometta R.M., Danias J. Tissue plasminogen activator reduces the elevated intraocular pressure induced by prednisolone in sheep. Exp Eye Res. 2014. 128. 114-116. DOI: 10.1016/j.exer.2014.10.004.Gerometta R., Kumar S., Shah S., Alvarez L., Candia O., Danias J. Reduction of steroidinduced intraocular pressure elevation in sheep by tissue plasminogen activator. Invest Ophthalmol Vis Sci. 2013. 54(13). 7903-7909. DOI: 10.1167/iovs.13-12801.Gerometta R., Kumar S., Shah S., Alvarez L., Candia O., Danias J. Reduction of steroidinduced intraocular pressure elevation in sheep by tissue plasminogen activator. Invest Ophthalmol Vis Sci. 2013. 54(13). 7903-7909. DOI: 10.1167/iovs.13-12801.

The authors declare that there are no conflicts of interest present.